265 related articles for article (PubMed ID: 29632962)
1. Policies and availability of orphan medicines in outpatient care in 24 European countries.
Sarnola K; Ahonen R; Martikainen JE; Timonen J
Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
[TBL] [Abstract][Full Text] [Related]
2. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
3. Pricing and reimbursement of orphan drugs: the need for more transparency.
Simoens S
Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
[TBL] [Abstract][Full Text] [Related]
4. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
5. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
6. Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia X; Gil A; Poveda-Andrés JL; Shepherd J; Tort M
Farm Hosp; 2019 Jul; 43(4):121-127. PubMed ID: 31276443
[TBL] [Abstract][Full Text] [Related]
7. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Gammie T; Lu CY; Babar ZU
PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
[TBL] [Abstract][Full Text] [Related]
8. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
9. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
10. Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019.
Badia X; Vico T; Shepherd J; Gil A; Poveda-Andrés JL; Hernández C
Orphanet J Rare Dis; 2020 Aug; 15(1):224. PubMed ID: 32859228
[TBL] [Abstract][Full Text] [Related]
11. Uptake and availability of new outpatient cancer medicines in 2010-2021 in Nordic countries - survey of competent authorities.
Sarnola K; Koskinen H; Klintrup K; Astrup C; Kurko T
BMC Health Serv Res; 2023 Dec; 23(1):1437. PubMed ID: 38110924
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the evolution in the access to orphan medicines in Spain].
Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
[TBL] [Abstract][Full Text] [Related]
13. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
14. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
Wonder M; Chin G
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
[TBL] [Abstract][Full Text] [Related]
15. Access to orphan drugs - comparison across Balkan countries.
Pejcic AV; Iskrov G; Jakovljevic MM; Stefanov R
Health Policy; 2018 Jun; 122(6):583-589. PubMed ID: 29729905
[TBL] [Abstract][Full Text] [Related]
16. Patient Access to Medicines for Rare Diseases in European Countries.
Detiček A; Locatelli I; Kos M
Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
[TBL] [Abstract][Full Text] [Related]
17. European pharmaceutical pricing and reimbursement conference.
Ehreth J; Williams D
Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):37-9. PubMed ID: 19371177
[TBL] [Abstract][Full Text] [Related]
18. Shining a light in the black box of orphan drug pricing.
Picavet E; Morel T; Cassiman D; Simoens S
Orphanet J Rare Dis; 2014 Apr; 9():62. PubMed ID: 24767472
[TBL] [Abstract][Full Text] [Related]
19. European Pharmaceutical Pricing and Reimbursement--SMi's 21st Annual Meeting (October 5-6, 2015--London, UK).
Kibble A; D'Souza P
Drugs Today (Barc); 2015 Oct; 51(10):609-12. PubMed ID: 26583303
[TBL] [Abstract][Full Text] [Related]
20. [Orphan diseases and orphan medicines: a Belgian and European study].
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
